MINNEAPOLIS--(BUSINESS WIRE)--March 30, 2006--In an announcement today, Humanetics Corporation said that the Food & Drug Administration (FDA) has approved the start of human trials for Humanetics’ promising new oral compound, NIC5-15, aimed at combating Alzheimer’s disease.
